204 related items for PubMed ID: 30916859
1. Sivelestat sodium hydrate treatment for refractory Kawasaki disease.
Ebata R, Yasukawa K, Nagai K, Saito Y, Higashi K, Homma J, Takada N, Takechi F, Saito N, Kobayashi H, Okunushi K, Hamada H, Kohno Y, Hanaoka H, Shimojo N.
Pediatr Int; 2019 May; 61(5):438-443. PubMed ID: 30916859
[Abstract] [Full Text] [Related]
2. Efficacy and safety of intravenous immunoglobulin plus prednisolone therapy in patients with Kawasaki disease (Post RAISE): a multicentre, prospective cohort study.
Miyata K, Kaneko T, Morikawa Y, Sakakibara H, Matsushima T, Misawa M, Takahashi T, Nakazawa M, Tamame T, Tsuchihashi T, Yamashita Y, Obonai T, Chiga M, Hori N, Komiyama O, Yamagishi H, Miura M, Post RAISE group.
Lancet Child Adolesc Health; 2018 Dec; 2(12):855-862. PubMed ID: 30337183
[Abstract] [Full Text] [Related]
3. Higher efficacy of infliximab than immunoglobulin on Kawasaki disease, a meta-analysis.
Li X, Tang Y, Ding Y, Chen Y, Hou M, Sun L, Qian G, Qin L, Lv H.
Eur J Pharmacol; 2021 May 15; 899():173985. PubMed ID: 33652059
[Abstract] [Full Text] [Related]
4. The time option of IVIG treatment is associated with therapeutic responsiveness and coronary artery abnormalities but not with clinical classification in the acute episode of Kawasaki disease.
Samadli S, Liu FF, Mammadov G, Wang JJ, Liu HH, Wu YF, Luo HH, Wu Y, Chen WX, Zhang DD, Wei W, Hu P.
Pediatr Rheumatol Online J; 2019 Jul 31; 17(1):53. PubMed ID: 31366406
[Abstract] [Full Text] [Related]
5. Targeted use of prednisolone with the second IVIG dose for refractory Kawasaki disease.
Kimura M, Harazaki M, Fukuoka T, Asakura I, Sakai H, Kamimaki T, Ohkawara I, Akiyama N, Tsurui S, Iwashima S, Shimomura M, Morishita H, Meguro T, Seto S.
Pediatr Int; 2017 Apr 31; 59(4):397-403. PubMed ID: 27743415
[Abstract] [Full Text] [Related]
6. Phase II Open Label Study of Anakinra in Intravenous Immunoglobulin-Resistant Kawasaki Disease.
Koné-Paut I, Tellier S, Belot A, Brochard K, Guitton C, Marie I, Meinzer U, Cherqaoui B, Galeotti C, Boukhedouni N, Agostini H, Arditi M, Lambert V, Piedvache C.
Arthritis Rheumatol; 2021 Jan 31; 73(1):151-161. PubMed ID: 32779863
[Abstract] [Full Text] [Related]
7. Importance of C-reactive protein level in predicting non-response to additional intravenous immunoglobulin treatment in children with Kawasaki disease: a retrospective study.
Iwashima S, Kimura M, Ishikawa T, Ohzeki T.
Clin Drug Investig; 2011 Jan 31; 31(3):191-9. PubMed ID: 21456105
[Abstract] [Full Text] [Related]
8. Cyclosporin A treatment for Kawasaki disease refractory to initial and additional intravenous immunoglobulin.
Suzuki H, Terai M, Hamada H, Honda T, Suenaga T, Takeuchi T, Yoshikawa N, Shibuta S, Miyawaki M, Oishi K, Yamaga H, Aoyagi N, Iwahashi S, Miyashita R, Onouchi Y, Sasago K, Suzuki Y, Hata A.
Pediatr Infect Dis J; 2011 Oct 31; 30(10):871-6. PubMed ID: 21587094
[Abstract] [Full Text] [Related]
9. Intravenous immune globulin plus corticosteroids in refractory Kawasaki disease.
Jibiki T, Kato I, Shiohama T, Abe K, Anzai S, Takeda N, Yamaguchi KI, Kanazawa M, Kurosaki T.
Pediatr Int; 2011 Oct 31; 53(5):729-735. PubMed ID: 21342358
[Abstract] [Full Text] [Related]
10. Ulinastatin therapy in kawasaki disease.
Iwashima S, Seguchi M, Matubayashi T, Ohzeki T.
Clin Drug Investig; 2007 Oct 31; 27(10):691-6. PubMed ID: 17803344
[Abstract] [Full Text] [Related]
11. Infliximab versus second intravenous immunoglobulin for treatment of resistant Kawasaki disease in the USA (KIDCARE): a randomised, multicentre comparative effectiveness trial.
Burns JC, Roberts SC, Tremoulet AH, He F, Printz BF, Ashouri N, Jain SS, Michalik DE, Sharma K, Truong DT, Wood JB, Kim KK, Jain S, KIDCARE Multicenter Study Group.
Lancet Child Adolesc Health; 2021 Dec 31; 5(12):852-861. PubMed ID: 34715057
[Abstract] [Full Text] [Related]
12. Corticosteroid pulse combination therapy for refractory Kawasaki disease: a randomized trial.
Ogata S, Ogihara Y, Honda T, Kon S, Akiyama K, Ishii M.
Pediatrics; 2012 Jan 31; 129(1):e17-23. PubMed ID: 22144699
[Abstract] [Full Text] [Related]
13. Effects of steroid pulse therapy on immunoglobulin-resistant Kawasaki disease.
Furukawa T, Kishiro M, Akimoto K, Nagata S, Shimizu T, Yamashiro Y.
Arch Dis Child; 2008 Feb 31; 93(2):142-6. PubMed ID: 17962370
[Abstract] [Full Text] [Related]
14. Clarithromycin Plus Intravenous Immunoglobulin Therapy Can Reduce the Relapse Rate of Kawasaki Disease: A Phase 2, Open-Label, Randomized Control Study.
Nanishi E, Nishio H, Takada H, Yamamura K, Fukazawa M, Furuno K, Mizuno Y, Saigo K, Kadoya R, Ohbuchi N, Onoe Y, Yamashita H, Nakayama H, Hara T, Ohno T, Takahashi Y, Hatae K, Harada T, Shimose T, Kishimoto J, Ohga S, Hara T.
J Am Heart Assoc; 2017 Jul 06; 6(7):. PubMed ID: 28684643
[Abstract] [Full Text] [Related]
15. High-Dose Aspirin is Associated with Anemia and Does Not Confer Benefit to Disease Outcomes in Kawasaki Disease.
Kuo HC, Lo MH, Hsieh KS, Guo MM, Huang YH.
PLoS One; 2015 Jul 06; 10(12):e0144603. PubMed ID: 26658843
[Abstract] [Full Text] [Related]
16. Delayed intravenous immunoglobulin treatment increased the risk of coronary artery lesions in children with Kawasaki disease at different status.
Qiu H, He Y, Rong X, Ren Y, Pan L, Chu M, Wu R, Shi H.
Postgrad Med; 2018 May 06; 130(4):442-447. PubMed ID: 29745742
[Abstract] [Full Text] [Related]
17. High neutrophil : lymphocyte ratio is associated with refractory Kawasaki disease.
Cho HJ, Bak SY, Kim SY, Yoo R, Baek HS, Yang S, Hwang IT, Ban JE.
Pediatr Int; 2017 Jun 06; 59(6):669-674. PubMed ID: 28097746
[Abstract] [Full Text] [Related]
18. Fever pattern and C-reactive protein predict response to rescue therapy in Kawasaki disease.
Nakagama Y, Inuzuka R, Hayashi T, Shindo T, Hirata Y, Shimizu N, Inatomi J, Yokoyama Y, Namai Y, Oda Y, Takamizawa M, Harita Y, Oka A.
Pediatr Int; 2016 Mar 06; 58(3):180-184. PubMed ID: 26222760
[Abstract] [Full Text] [Related]
19. Predictors of intravenous immunoglobulin resistance and coronary artery aneurysm in patients with Kawasaki disease.
Chantasiriwan N, Silvilairat S, Makonkawkeyoon K, Pongprot Y, Sittiwangkul R.
Paediatr Int Child Health; 2018 Aug 06; 38(3):209-212. PubMed ID: 29768976
[Abstract] [Full Text] [Related]
20. Seasonality of i.v. immunoglobulin responsiveness in Kawasaki disease.
Kido S, Ae R, Kosami K, Matsubara Y, Makino N, Sasahara T, Kuwabara M, Aoyama Y, Yashiro M, Yanagawa H, Nakamura Y.
Pediatr Int; 2019 Jun 06; 61(6):539-543. PubMed ID: 30980447
[Abstract] [Full Text] [Related]
Page: [Next] [New Search]
